SOURCE: MarketResearch.com

MarketResearch.com

October 03, 2011 08:08 ET

Alternatives to Surgery & Superior Outcomes Are Driving Wider Adoption of Orthobiologics

ROCKVILLE, MD--(Marketwire - Oct 3, 2011) - MarketResearch.com has announced the addition of the new report "Orthobiologics Market to 2016 - Alternatives to Surgery and Superior Outcomes are Driving Wider Adoption of Orthobiologics," to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/GBI-Research-v3759/Orthobiologics-Alternatives-Surgery-Superior-Outcomes-6501704/

The global orthobiologics market was valued at $4.3 billion in 2009, and is forecast to reach $9.6 billion in 2016, which represents a compound annual growth rate (CAGR) of 12%. Bone graft substitutes will remain the largest segment in the market, with a value of $5.3 billion by 2016. Growth in the market is primarily being driven by the increasing incidence of arthritis, an increasingly elderly population, and higher obesity rates. Globally, about 350 million people have arthritis, and more than half of those with arthritis, are under 65 years of age. Also, advances in technology, such as the development of nanotechnology coatings for use in wear-resistant orthopedic devices, and injectable bones, which are biodegradable and can fill any cavity shape, taking on similar characteristics to normal bone, are expected to drive the market in the near future.

The US orthobiologics market was valued at $2.3 billion in 2009, and is expected to reach $6 billion in 2016, which represents a CAGR of 15% for the period. The US remains the largest orthobiologics market in the world, accounting for more than 50% of the global orthobiologics market in 2009. The orthobiologics market in the US going forwards is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents.

The incidence of arthritis has been growing steadily, mainly due to an increase in obesity rates and an increase in the population over the age of 65. Studies have shown that more than 50% of people over 65 years of age, go on to develop osteoarthritis, and worldwide, 350 million people have arthritis. According to the US Centre of Disease Control (CDC), 47.8 million people in the US were affected by some form of arthritis during 2005. It is projected that by 2030, physician-diagnosed arthritis will reach 67 million, or 25% of the adult population. Also, the prevalence of back pain is increasing, and is estimated to be highest among middle aged individuals, between 30 to 50 years old. The annual incidence of lower back pain in the US and Europe is approximately 5% of the total population. Worldwide, 200 million people are at risk of a fragility fracture, and 40% of women and 14% of men older than 50 years, will experience a fragility fracture.

Numbers suffering from orthopedic diseases are expected to grow in developing countries, due to people leading more sedentary lives, changes in diet, and urbanization, which all lead to increasing obesity rates, and ultimately to arthritis and other orthopedic diseases. Obesity rates have increased globally over the past few decades, with currently more than one billion adults overweight worldwide, and at increased risk of developing arthritis.

The orthobiologics product pipeline is strong, with about 134 products making their way to market. These products are aimed at reducing rejection rates, stimulating the growth of bone and improving patient outcomes. The advantages offered and the simplicity in use of many of these pipeline products is expected to increase their uptake. Nanotechnology will be the key driver of growth in the orthobiologics market in the near future.

There are products in the pipeline which have nanotechnology coatings, for use in wear-resistant orthopedic devices, specifically for spinal implants. Due to this coating, the products offer a higher level of durability, thus increasing demand for them. Also, companies are developing injectable bones which are biodegradable, and are able to stabilize fractured bones, offering superior strength, rapid setting and mouldable properties.

Products offering greater durability, reductions in inflammation, and which improve the quality of life, are expected to drive future demand for orthobiologics.

For more information, visit http://www.marketresearch.com/GBI-Research-v3759/Orthobiologics-Alternatives-Surgery-Superior-Outcomes-6501704/

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit www.MarketResearch.com.

Contact Information

  • Contact:
    Veronica Franco
    MarketResearch.com
    Email Contact
    240.747.3016